Strand Therapeutics vs Stipple Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic gates. STX-003 IV delivery entering clinic 2026. Phase 1 confirmed CR at ASCO 2025.
About
Strand Therapeutics is developing programmable mRNA — modified messenger RNA that incorporates synthetic gene circuits (logic gates) that restrict therapeutic protein expression to the tumor microenvironment. The company raised $153 million in Series B financing in August 2025, bringing total funding to $256 million at a ~$571 million valuation. Strand presented Phase 1 data at ASCO 2025 showing a confirmed complete response for STX-001, and its STX-003 program — which uses intravenous delivery rather than intratumoral injection — is entering clinical testing in 2026.
Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.
About
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.